Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549297 | 0.86 | CHRNB2 (0.51) | CHRNB2CHRNA4TAAR1HTR2ANOS2 | |
| SCHEMBL7263992 | 0.82 | CHRNB2 (0.51) | CHRNB2CHRNA4TAAR1HTR2ANOS2 | |
| SCHEMBL2911081 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4TAAR1HTR2ANOS2 | |
| SCHEMBL147186 | 0.78 | CHRNB2 (0.54) | CHRNB2CHRNA4TAAR1HTR2ANOS2 | |
| SCHEMBL2701320 | 0.77 | CHRNB2 (0.50) | CHRNB2CHRNA4TAAR1HTR2ANOS2 | |
| SCHEMBL10458379 | 0.77 | TAAR1 (0.41) | CHRNB2CHRNA4TAAR1HTR2AHRH1 | |
| SCHEMBL10456715 | 0.77 | SCN1A (0.57) | HTR2AHRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18357927 | 0.77 | CHRNB2 (0.46) | CHRNB2CHRNA4TAAR1HTR2ANOS2 | |
| SCHEMBL17892069 | 0.77 | CHRNB2 (0.50) | CHRNB2CHRNA4TAAR1HTR2ANOS2 | |
| SCHEMBL9216785 | 0.76 | CHRNB2 (0.77) | CHRNB2CHRNA4TAAR1HTR2ANOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286202-A1 | New Compounds | REN, PCSK9, FURIN | CHRNB2 4721/4885CHRNA4 4624/4885TAAR1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.